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Summary
Multiple endocrine neoplasia type 1 (MEN1) is an au-
tosomal dominant syndrome predisposing to tumors of
the parathyroid, endocrine pancreas, anterior pituitary,
adrenal glands, and diffuse neuroendocrine tissues. The
MEN1 gene has been assigned, by linkage analysis and
loss of heterozygosity, to chromosome 11q13 and re-
cently has been identified by positional cloning. In this
study, a total of 84 families and/or isolated patients with
either MEN1 or MEN1-related inherited endocrine tu-
mors were screened for MEN1 germ-line mutations, by
heteroduplex and sequence analysis of the MEN1
gene–coding region and untranslated exon 1. Germ-line
MEN1 alterations were identified in 47/54 (87%)
MEN1 families, in 9/11 (82%) isolated MEN1 patients,
and in only 6/19 (31.5%) atypical MEN1-related in-
herited cases. We characterized 52 distinct mutations in
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a total of 62 MEN1 germ-line alterations. Thirty-five of
the 52 mutations were frameshifts and nonsense mu-
tations predicted to encode for a truncated MEN1 pro-
tein. We identified eight missense mutations and five in-
frame deletions over the entire coding sequence. Six
mutations were observed more than once in familial
MEN1. Haplotype analysis in families with identical
mutations indicate that these occurrences reflected
mainly independent mutational events. NoMEN1 germ-
line mutations were found in 7/54 (13%) MEN1 fam-
ilies, in 2/11 (18%) isolated MEN1 cases, in 13/19
(68.5%) MEN1-related cases, and in a kindred with fa-
milial isolated hyperparathyroidism. Two hundred
twenty gene carriers (167 affected and 53 unaffected)
were identified. No evidence of genotype-phenotype cor-
relation was found. Age-related penetrance was esti-
mated to be 195% at age 130 years. Our results add to
the diversity ofMEN1 germ-line mutations and provide
new tools in genetic screening of MEN1 and clinically
related cases.
Introduction
Multiple endocrine neoplasia (MEN) syndromes are fa-
milial disorders characterized by the combined occur-
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rence of tumors in several endocrine glands. In MEN
type 1 (MEN1; Wermer syndrome [MIM 131100]), the
disease phenotypes include hyperplasia and/or tumors of
the parathyroid, pancreatic islets, anterior pituitary, en-
docrine cells in the gastro-duodenal and thymic-bronchic
tracts, and adrenocortical glands and lipoma (Wermer
1954; Sheperd 1991; Metz et al. 1994). Beyond the typ-
ical clinical manifestations, recent studies have suggested
that cutaneous lesions and nervous-tissue tumors also
are observed in MEN1 patients (Kato et al. 1996; Trump
et al. 1996; Darling et al. 1997; Giraud et al. 1997).
MEN1 is transmitted as an autosomal dominant trait
with high penetrance. Prognosis in MEN1 patients is
related to hormonal hypersecretion by tumors, such as
hypergastrinemia causing severe peptic ulcer disease
(Zollinger-Ellison syndrome [ZES]), primary hyperpar-
athyroidism, and acute forms of hyperinsulinemia. Some
tumors, primarily in pancreas, thymus, and bronchi, un-
dergo malignant progression. The prevalence of MEN1
has been estimated as 1/30,000–1/50,000, on the basis
of autopsy and epidemiological studies (Metz et al.
1994).
The MEN1 gene has been localized to chromosome
11q13, by both linkage analysis and deletion mapping
in tumor genomic DNA (Larsson et al. 1988; Friedman
et al. 1989; Bystro¨m et al. 1990). Loss of heterozygosity
(LOH) at 11q13 in MEN1-related endocrine tumors has
suggested that the MEN1 gene–encoded protein could
be a tumor-suppressor gene, consistent with the two-hit
model according to Knudson (1971; also see Friedman
et al. 1989; Bystro¨m et al. 1990; Radford et al. 1990).
The MEN1 gene recently has been cloned (Chandrasek-
harappa et al. 1997; Lemmens et al. 1997) and spans
≈9 kb of genomic DNA containing 10 exons. Exon 1
and the 3′ 832 bp of exon 10 are untranslated. A major,
2.9-kb MEN1 transcript has been detected in a variety
of human tissues, and an additional, 4-kb transcript has
been identified in pancreas and thymus (Lemmens et al.
1997). Germ-line mutations have been identified in most
MEN1 families tested. The observed mutations include
nonsense, missense, and frameshift mutations scattered
throughout the entire coding region (Argawal et al.
1997; Chandrasekharappa et al. 1997; Lemmens et al.
1997; Mayr et al. 1997; Shimizu et al. 1997; Bassett et
al. 1998). Results published so far suggest an absence
of correlation between genotype (i.e., mutation location
and type) and the clinical phenotype. A common feature
among the mutations described to date is a likely loss
of function of the resulting MEN1 protein.
Here we report the results of mutation analysis in 54
independent MEN1 families, 11 isolated MEN1 cases,
and 19 isolated and/or familial cases with uncommon
associations of MEN1-related tumors, defined as atyp-
ical situations. We also screened one familial isolated
hyperparathyroidism (FIHPT). All these patients and
families have been collected since 1993, within the
framework of the French Groupe d’Etude des Ne´oplasies
Endocriniennes Multiples (GENEM) clinical network.
Subjects and Methods
Patients and Families
Patients and families were identified through the GE-
NEM network (Calender et al. 1995), including 84 pro-
bands and related subjects from 54 unrelated MEN1
families, 11 isolated MEN1 patients, and 19 individuals
with uncommon associations of MEN1-related tumors.
Patients were classified as either typical MEN1 and atyp-
ical MEN1-related cases. Typical MEN1 in both familial
and isolated contexts was defined according to the cri-
teria established at the 5th International MEN Work-
shop (Skogseid et al. 1995a, 1995b). In brief, MEN1
was diagnosed in patients with at least three of the five
major lesions described in the syndrome, including tu-
mors of parathyroid glands (HPT), endocrine pancreas
(PET), anterior pituitary (PIT), thymic/bronchic neu-
roendocrine tissues (NET), and adrenal glands (ADR).
Familial MEN1 (denoted by an arabic numeral with a
prefix “F”) was characterized by the presence of both a
proband affected by at least two MEN1 major lesions
and a first-degree relative with one major lesion (HPT
and/or PET and/or PIT and/or NET and/or NET and/
or ADR). Patients with unknown family history at the
time of the study were defined as isolated MEN1 cases
(denoted by an arabic numeral with a prefix “I”). Pa-
tients and families with uncommon inherited/isolated as-
sociations of no more than of the major lesions occurring
in MEN1 were classified as atypical MEN1-related cases
(denoted by an arabic numeral with a prefix “A”). One
family was identified as having FIHPT, on the basis of
a long-term (x10 years) follow-up. Differential diag-
nosis of FIHPT led us to exclude familial hypocalci-
uric hypercalcemia (FHH) related to the calcium sen-
sor–receptor gene isolated on chromosome 3 (Pollak et
al. 1993). In the family that we studied, FHH was ex-
cluded on the basis of both clinical evidence of hyper-
calciuria and histopathological observations of multi-
glandular parathyroid adenomas and hyperplasia in two
probands.
For each patient and family member, clinical infor-
mation included tests of total and/or free calcemia, par-
athyroid hormone 1-84, 24-h urinary calcium, glycemia,
peptide C and insulin, basal gastrin, prolactin, growth
hormone, and dynamic endocrine, related to each clin-
ical situation, when available. Radiological studies (ab-
dominal echography and/or echoendoscopy, thoracic
and abdominal computed-tomography scan, pituitary
magnetic-resonance imaging, and standard thoracic X-
ray) were performed on all patients included in this re-
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port, according to GENEM recommendations (Chanson
et al. 1997). Histopathological reports were examined
carefully for each patient treated by surgery. In this study,
71.8% (120/167) of the subjects classified as affected by
MEN1 were diagnosed clinically, whereas 28.2% (47/
167) were detected through biochemical screening. In
the latter group, most (x90%) were diagnosed as hav-
ing primary HPT (pHPT). When a mutation was iden-
tified in a proband, all available related members in the
family were screened for the presence of the variant. Fifty
unrelated control individuals (100 chromosomes) were
screened for the presence of any of the missense variants
found, to exclude frequent polymorphisms.
MEN1 Gene–Mutation Analysis
DNA and RNA extraction and cDNA synthe-
sis.—DNA was extracted from peripheral blood lym-
phocytes and/or Epstein-Barr–virus immortalized lym-
phoblastoid cell lines. A modification of the protocol
described by Sambrook et al. (1989) was used for RNA
extraction. In brief, the cell pellets were lysed in the RNA
extraction buffer containing 4 M guanidinium thiocy-
anate, 25 mM sodium citrate, 1% sodium laurylsarco-
sine, and 0.2 M b-mercaptoethanol. The solution was
extracted with a same volume of phenol saturated with
water, 0.1 vol of 2 M sodium acetate (pH 4.0), and 0.2
vol of chloroform, and then it was precipitated with
isopropanol and was washed with 70% ethanol. Single-
strand cDNA was synthesized with 2 mg total of RNA,
by use of the first-strand cDNA synthesis kit (Pharmacia)
according to the manufacturer’s instructions.
Reverse transcription–PCR (RT-PCR) was performed
with forward and reverse primers at nucleotide positions
325 and 1340, respectively, of the MEN1 cDNA se-
quence, by use of Taq polymerase (Red Hot DNA Poly-
merase; Applied Biosystems) according to the manufac-
turer’s recommendations. Primers sequences used for
RT-PCR were as follows: forward, 5′-GCC GTC GAC
CTG TCC CTC TAT C-3′ (in exon 2); and reverse, 5′-
GAA GCA CTC AGG GTC CTG GAG-3′ (in exon 9).
Heteroduplex (HD) screening.—Exons 2–10 of the
MEN1 gene were amplified from genomic DNA by PCR
using a set of specific primers of the MEN1 coding re-
gion, as described and referenced in a previous report
(Lemmens 1997). Exon 1 untranslated sequence was am-
plified by use of primers E1F (5′-ACG CTT CCT GCC
TGG TGG TCG G-3′) and E1R (5′-CTG CTG GGA CAT
GAA GTC CCG-3′), which allowed the amplification of
a region from, respectively, 33 bp upstream of the 5′ end
of exon 1 and 45 bp downstream of the 3′ end of exon
1. For HD analysis, the following combinations of prim-
ers were used: 1 forward and 4R (exon 2), 5F and 7R
(exons 3 and 4), 8F and 9R (exons 5 and 6), 10F and
10R (exon 7), 11F and 11R (exon 8), 12F and 12R (exon
9), and 13F and 15R (exon 10). MEN1 cDNA was avail-
able for 15 probands and was screened when no mu-
tation was found in the genomic sequence. PCR reac-
tions were performed in a total volume of 15 ml
containing 50 ng of genomic DNA and/or cDNA, 1 mM
each primer, 0.5 mCi of a[33P]-dATP (1–3 mCi/mmol)
(ICN), and 0.1 U of Taq DNA polymerase (Eurobio).
PCR was performed in a Perkin Elmer Cetus model 9600
sequencer, as follows: 96C for 3 min; 32 cycles of 96C
for 30 s, annealing temperature for 30 s, and 72C for
1 min; and 72 for 7 min. PCR products were denatured
at 98C for 5 min and were cooled to room temperature
for x30 min, to induce HD formation. DNA fragments
were electrophoresed through 0.75 # MDE gel (FMC
BioProducts) at 600 V for 14 h in 0.6 # Tris-borate
buffer, by use of a vertical gel-electrophoresis apparatus
(Biorad). Gels were dried and exposed to Kodak BioMax
MR film. All variant bands found were subsequently
sequenced.
Sequence analysis.—The sequencing reaction was per-
formed directly from PCR-amplified DNA or cDNA, by
use of the PRISM Ready Reaction Dye Deoxyterminator
cycle sequencing kit (Perkin Elmer), and were run on an
automated sequencer (model ABI 377; Applied Biosys-
tems), with the same primers as had been used for HD
analysis.
Southern blot analysis.—a search for large genomic
rearrangements was performed by two independent
Southern blot experiments, with EcoRI and with KpnI
(New England Biolabs). In brief, 5 mg of DNA were
cleaved with either EcoRI or KpnI and were separated
by 1% agarose gel electrophoresis and then were trans-
ferred to Hybond N (Amersham) membranes. The
membranes were hybridized to a 32P-labeled probe cor-
responding to the MEN1 cDNA. Prehybridization, hy-
bridization, and autoradiography were performed ac-
cording to standard techniques.
Genotype-Phenotype Correlation Studies
For each phenotype of interest (e.g., HPT and/or PET
and/or PIT and/or NET and/or ADR), the proportions
of affecteds within each mutation class were compared,
by a standard x2 test. For the less common phenotypes
(i.e., ADR and NET), an exact hypergeometric test was
used. To ensure that sample sizes were adequate, mu-
tations were grouped into three classes: frameshifts or
nonsense mutations in exons 2–5, frameshifts or non-
sense mutations in exons 6–10, and missense mutations
regardless of location within the gene.
Linkage and Haplotypes
Haplotype analysis using polymorphic markers was
performed in every MEN1 family with a minimum of
two affected members, as described elsewhere (Larsson
Table 1








F1 FS 67 310dup5-ter120 HPT, PIT THYR
F2 FS 76 337delC-ter118 HPT, PET/ZES ADR
F3 FS 83 359del4-ter116 HPT, PET/ZES
F4 FS 83 359del4-ter116 HPT, PIT
F5 FS 83 359del4-ter116 HPT, PET/ZES
F6 FS 84 360dupGT-ter119 HPT, PET MEL
I1 NS 96 Gln96ter HPT, PET, PIT THYR
F7 NS 98 Arg98ter HPT, PET, PIT ADR
F8 NS 98 Arg98ter HPT, PET/ZES, NET ADR
F9 NS 108 Arg108ter HPT, PET, NET LIP, NET-meta
F10 FS 110 437ins-GG-ter119 HPT, PET, PIT NET, ADR
A1 NS 133 Tyr133ter HPT, PIT
Exon 3:
I2 MS 172 Asp172Tyr HPT, PET/ZES, PIT
F11 IF 197 699DELACC HPT, PET, NET, PIT NET-meta
I3 FS 210 738del4-ter222 HPT, PET, PIT
F12 SP 218 764GrT HPT, PIT
Exon 4:
F13 FS 222 776delC-ter223 HPT, PET, PIT ADR
F14 FS 223 778delT-ter280 HPT, PET, PIT ADR, LIP
A2 MS 223 Leu223Pro HPT, PET
F15 NS 261 Arg261ter HPT, PET, PIT
Intron 4:
F16 SP 8931GrT HPT, PET, PIT, NET
A3 SP 894-1GrC HPT, NET
Exon 5:
I4 NS 265 Tpr265ter HPT, PET, PIT
F17 FS 272 924insC-ter316 HPT, PET, NET NET-meta
Exon 7:
F18 MS 314 Arg314Pro HPT, PET
I5 FS 315 1054insA-ter316 HPT, PET/ZES, PIT
F19 MS 337 Ala337Asp HPT, PET
I6 MS 341 Trp314Arg HPT, PET ADR
Exon 8:
F20 MS 368 Ala368Asp HPT, PET/ZES, PIT
Exon 9:
F21 FS 397 1300delC-ter557 HPT, PET ADR
F22 FS 405 1325delG-ter444 HPT, PET, PIT THYR
F23 NS 415 Arg415ter HPT, PET, NET, PIT CNS
I7 FS 418 1363delAC-ter447 HPT, PET, PIT
F24 IF 418 1362del12 HPT, PET, NET, PIT THYR
F25 MS 418 Asp418Asn HPT, PET, PIT
F26 FS 422 1374delA-ter444 HPT, PET, NET, PIT NET-meta
F27 IF 425 1384delAGG HPT, PET/ZES, PIT ADR, CNS
F28 FS 438 1424del4-ter443 HPT, PET, NET, PIT ADR
F29 FS 447 1449del11-ter444 HPT, PET/ZES
Intron 9:
A4 SP 14604del2 HPT, PIT
Exon 10:
F30 IF 459 1487ins6 HPT, PET, PIT
F31 FS 460 1491insCC-ter496 PET/ZES, PIT
F32 FS 460 1499dup8-ter561 HPT, PET, PIT PET-meta
F33 NS 460 Arg460ter HPT, PIT ADR
F34 NS 460 Arg460ter HPT, PIT
I8 FS 467 1508ins-ter564 HPT, PET/ZES, PIT
F35 FS 499 1607delA-ter558 HPT, PET/ZES, PIT ADR
I9 FS 507 1630insC-ter530 HPT, PIT ADR
F36 FS 514 1650insC-ter530 HPT, ZES
(continued)





Mutationa Codon Mutation Clinical Featuresb
Associated
Lesion(s)c
F37 FS 514 1650insC-ter530 HPT, PET, PIT
F38 FS 514 1650insC-ter530 HPT, PIT, NET NET-meta
F39 FS 514 1650insC-ter530 HPT, PET/ZES
F40 FS 514 1650delC-ter558 HPT, PIT, ZES
F41 FS 514 1650delC-ter558 HPT, PET, PIT
F42 NS 527 Arg527ter HPT, PET, NET ADR
F43 NS 527 Arg527ter HPT, PET, NET, PIT ADR
F44 NS 536 Gln536ter HPT, PET/ZES THYR
F45 FS 550 1768delT-ter558 HPT, ZES, PIT
F46 FS 550 1768delT-ter557 HPT, PET, PIT
A5 MS 555 Ser555Asn HPT, PET
F47 IF 557 1780deAGA HPT, PET, PIT
A6 FS 558 1782delA-ter558 HPT, PIT
a SP  splice junction and intronic mutations; all other abbreviations are as defined in the text.
b ZES  ZES individuals/families affected by duodenal gastric ulcers with or without identified tumors
to date; all other abbreviations are as defined in the text.
c THYR  thyroid epithelial adenoma, MEL  melanoma, NET-meta  metastatic evolution of NET,
CNS  meningioma, ependymoma, and/or gliobastoma of CNS, and PET-meta  metastatic evolution of
NET; all other abbreviations are as defined in the text.
et al. 1995). Common microsatellite loci used were, from
centromere to telomere, D11S480, D11S1883, PYGM,
D11S449, D11S1889, and D11S913. Families in which
no mutation was found and for which sufficient numbers
of DNA samples were available were analyzed by mul-
tipoint linkage analysis with markers D11S480, PYGM,
and D11S913, by means of the VITESSE program (ver-
sion 1.0) (O’Connell and Weeks 1995). A dominant
mode of inheritance was assumed, with a disease-allele
frequency of .000025 and age-related penetrance max-
imizing at age 50 years, as estimated in previous studies
(Sheperd 1991; Trump et al. 1996).
Results
Germ-Line Mutations
Germ-line mutations were identified in a total of 47/
54 (87%) MEN1 families, 9/11 (82%) patients with iso-
lated MEN1, and 6/19 (31.5%) probands who were
atypical MEN1-related cases. We identified 52 distinct
mutations in a total of 62 MEN1 germ-line alterations,
which are detailed in table 1 (also see Genome Data-
base). The 52 mutations occurred throughout the entire
coding sequence and three exon/intron boundaries (fig.
1). Most (45/62) mutations were located in exons 2, 9,
and 10. Twenty-five mutations were frameshifts (dele-
tions and insertions), 10 were nonsense mutations, 4
were splice-junction mutations, 8 were missense muta-
tions, and 5 were in-frame deletions or insertions. HD
screening of genomic DNA detected 44 (≈85%) of the
52 mutations, with high and mild sensitivity, respec-
tively, for frameshifts (25/25 [100%]) and point muta-
tions (12/18 [67%]). HD screening therefore was con-
sidered a powerful tool in the identification of MEN1
families with identified germ-line mutation. The majority
(35/52) of these germ-line mutations were predicted to
result in premature translation termination. Of the
52 independent mutations, 8 (359del4, Arg98ter,
Trp265ter, Asp418Asn, Arg460ter, Arg527ter,
1650insC, and 1650delC) have been described elsewhere
(Argawal et al. 1997; Mayr et al. 1997; Shimizu et al.
1997; Bassett et al. 1998). In our series, eight mutations
were observed more than once: 359del4 was identified
in three families; 1650insC was found in four families;
and each of the mutations Arg98ter, Arg460ter,
1650delC, Arg527ter, and 1768delT were identified in
two families.
Four missense variants were detected in four unrelated
typical MEN1 families (F18, F19, F20, and F25) and
were shown to cosegregate with the disease. Four mis-
sense mutations also were identified, in two isolated
MEN1 patients (patients 12 and 16) and in two MEN1-
related cases (individuals A2 and A5). Only one muta-
tion (Asp418Asn) has been described elsewhere (Bassett
et al. 1998). These missense mutations were not ob-
served in 50 normal unrelated individuals (100 chro-
mosomes) and thus likely represent true deleterious
mutations.
One mutation (in F16), which was not detected
through HD analysis of genomic DNA, was detected at
the cDNA level, by RT-PCR (table 1). Further genomic
DNA sequencing revealed a GrT point mutation at the
first base of intron 4, in the donor-splice junction of exon
4/intron 4, at position 8931. This mutation alters
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Figure 1 Cosegregation analysis of 337delC MEN1 germ-line
mutation in exon 2, detected by HD screening for the disease and for
11q13 haplotypes in part of a large MEN1 family. Five distinct hap-
lotypes (A–E) have been identified, each of which includes alleles for
markers D11S480, D11S1883, PYGM(caga), D11S449, D11S1889,
and D11S913, from centromere to telomere, respectively. The hap-
lotype associated with the disease was “A” (see below). A plus sign
() denotes mutant-gene carrier status, as defined by haplotypes and
identification of 337delC by HD screening. Affected gene carriers pre-
sented the following lesions: individual 2, HPT and ADR; individual
3, HPT; individual 5, HPT; individual 6, HPT and PET; and individual
7, HPT and ADR. Individual 10 was defined as an asymptomatic gene
carrier at age 38 years, during a recent (X6 mo prior to this study)
screening excluding any endocrine biological and/or biochemical
abnormalities.
an Hphl site and thus can be detected easily by
PCR–restriction-enzyme analysis (fig. 2A). RT-PCR and
cDNA sequence analysis (fig. 2B) revealed complete
skipping of the in-frame exon 4 from the MEN1 tran-
script, which removed 43 amino acids from the MEN1
protein. Splice-site mutations were found in three other
cases, at the donor sites of exons 3 and 9 and at the
acceptor sites of exon 5, at positions 764, 8941, and
14604, respectively. cDNA was not available from af-
fected individuals carrying these splice-site alterations.
However, all three mutations affect highly conserved
splice consensus sequences. No mutation was found in
the untranslated part of the MEN1 gene, including exon
1 and the 5′ untranslated portion of exon 2.
Only six mutations were found in 19 atypical MEN1-
related familial cases (patients and/or first-degree rela-
tives with no more than two MEN1-related tumors). As
shown in table 1, atypical families were characterized
by single endocrine lesions occurring in first- or second-
degree relatives. In six families with MEN1 mutations,
clinical lesions found in two individuals from the same
family were HPT and PIT (in A1, A4, and A6), HPT
and PET (in A2 and A5), and HPT and a bronchic NET
(in A3).
Polymorphisms in the MEN1 Gene
Five polymorphisms were observed in the MEN1
gene. One of them occurred in intron 1 (position 16),
at nucleotide 2249, as a CrG transition observed in
20% of the normal population; two of them had
been described elsewhere; two of them, Ser145Ser
(AGCrAGT) and Asp418Asp (GACrGAT), were ob-
served at respective frequencies of l% and 45%, and the
same polymorphisms have been reported, at similar al-
lele frequencies, by others (Argawal et al. 1997; Bassett
et al. 1998). A polymorphism in exon 3 led to an
ArgrGln substitution at codon 171. This benign poly-
morphism also has been observed, in the same allelic
proportion (5%), in a National Institutes of Health study
(Argawal et al. 1997). We identified a new polymor-
phism in exon 1, at nucleotide 1755, TrA (32%) and
TrC (12%).
Haplotype Analysis in MEN1 Families with Identified
Mutations
To check for a possible founder effect in the case of
recurrent mutations, haplotype analysis were performed
with 11q13 polymorphic markers surrounding the
PYGM and MEN1 loci (Larsson et al. 1995; Courseaux
et al. 1996). Linkage data were available for six of the
eight recurrent mutations occurring in 15 families in
which at least two affected individuals have been sam-
pled (table 2). Families with recurrent mutations
359del4, Arg98ter, Arg460ter, and Arg527ter were
shown to carry apparently different haplotypes; thus, a
founder effect is not a likely explanation of the recur-
rence of these mutations. Of four families with mutation
1650insC, two of them, F36 and F37, carry a common
haplotype, suggesting a common ancestor (table 2).
Families F40 and F41, carrying mutation 1650delC,
have both a partial haplotype match for affected indi-
viduals, in the proximal region from D11S480 to
PYGM, and a divergence in the distal part, from
D11S449 to D11S913. These two families were from
the same geographic origin in northern France. Knowing
that the MEN1 gene is located ≈55 kb distal to PYGM
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Figure 2 A, Detection of mutation 8931 in intron 4 in a selected nuclear part of F16, by PCR–restriction-enzyme analysis. A point
mutation has caused a GrT substitution in the donor splice site of intron 4 and results in the loss of an HpHI restriction-enzyme site from the
normal (wild-type [WT]) sequence. This generates a large, 692-bp fragment. PCR was performed by means of primers 4F and 6R, as referenced
elsewhere (Lemmens et al. 1997). Detection of mutations was thus facilitated in F16, in other affected members. Patients 3 (age 35 years) and
4 (age 65 years) were both affected by HPT, PET, and PIT. The unaffected individuals (1 and 5) were homozygous for the wild-type sequence,
and the affected individuals (3 and 5) were heterozygous for the wild-type sequence. Size markers are designated as “s.m.” B, 8931 mutation
in intron 4, which results in the in-frame skipping of exon 4 in MEN1 cDNA. RT-PCR of the MEN1 gene was performed in unaffected and
affected members of family F16. Primers used were forward 2f4 (Lemmens et al. 1997) and reverse 1121-SK21139 at position 1268 (authors’
unpublished data), generating an 860-bp fragment in wild-type cDNA. Deletion of exon 4 in affected members such as individual 3 leads to
an additional fragment, ≈730 bp, in concordance with the heterozygous removal of exon 4 (129 nucleotides). Individuals denoted as l–3 are
the same as those shown in the pedigree in panel A. A schematic representation of the in-frame deletion of exon 4 as detected by cDNA sequence
analysis has been provided on the left-hand side of the figure.
(Lemmens et al. 1997), we could expect that F40 and
F41 are genetically related if a recombination event is
assumed to have occurred, during the genetic history of
these families, in the ≈500–600-kb interval between
MEN1 locus and D11S449.
Clinical Expression in Mutant-Gene Carriers
The wild-type or mutant-MEN1 carrier status was
established in 356 individuals from 47 MEN1 families
and in 9 isolated MEN1 patients in whom MEN1 mu-
tations had been identified. Two hundred twenty gene
carriers were identified. Age-related penetrance was es-
timated to 25% at age 0–20 years, 75% at age 20–30
years, and x95% at age 130 years. Of the 220 gene
carriers, 24.1% (53/220) were asymptomatic (mean age
19.5 years), 21.4% (47/220) were detected by biochem-
ical screening (mean age 34.5 years), and 54.5% (120/
220) had clinical symptoms (mean age 47.3 years). In
the two latter groups, pHPT has been the first lesion
diagnosed in 150 patients (90%) by biological screening
of families, before genetic analysis. The youngest patient
in the group of symptomatic gene carriers was a 6-year-
old boy who was affected by insulinoma, in an MEN1
family. The oldest age among asymptomatic gene car-
riers was 70 years, in a large, previously documented
MEN1 family showing malignant phenotypes for neu-
roendocrine tumors (Giraud et al. 1997). Our obser-
vations clearly indicate that MEN1 germ-line mutations
can be, in some situations, not fully penetrant. We con-
firm the high prevalence of pHPT as the first and most
common lesion during the natural history of MEN1.
Genotype-phenotype correlation was analyzed by
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Table 2
Haplotype Analysis in MEN1 Families/Patients with Recurrent Mutations
MARKER
HAPLOTYPE INa
359del4 Arg98ter Arg460ter 1650insC 1650delC Arg527ter
F3 F4 F5 F7 F8 F33 F34 F36 F37 F38 F39 F40 F41 F42 F43
D11S480 8 8 4 6 3 4 8 8 8/4 8 4/5 8 8 5 8
D11S1883 ) ) ) 11 6/9 ) ) ) ) ) ) ) ) 8 3
PYGM(caga) 6 3 9/1 9 11 7 9 14 14/16 7 13 13 13 12 12
D11S449 15/18 15 17/18 ) ) 2 17 15 15/14 18 15/19 16 12 15 16
D11S1889 ) ) ) 3 2 3 3 ) ) ) ) ) ) 2 3
D11S913 3 2 4 4 4 3 3/4 3 3 2 4 3 4 4 3/4
a Haplotypes shown refer only to the affected (or risk-associated) haplotypes in each family. In families with poor informativity
or in which a unique patient was analyzed, both alleles of a marker could be linked to the disease and thus have been given (with
“/” between them). Common haplotypes are underlined. For F40 and F41, the shared proximal haplotype (D11S480–PYGM)
could suggest a recombination event occurring between PYGM-MEN1 and D11S449. All the families listed here were analyzed
in a single experiment, to allow a uniform designation of alleles.
comparison of clinical expression in mutant gene carriers
and both location and type of mutations within the cod-
ing sequence. No statistical differences in the gene car-
riers with specific clinical phenotypes could be identified
as a function of either type of mutations (missense/in
frame [MS/IF] vs. frameshift/nonsense [FS/NS]) ( 2x 
; ; 4 df), location in the gene (exons 2–6 vs.0.99 P x .90
exons 7–10) ( ; ; 4 df), or type and2x  3.47 P x .65
location simultaneously ( ; ; 8 df). Al-2x  5.4 P x .80
though, globally, we could rule out only large effects of
mutation type and position, we cannot exclude the pos-
sibility of mutation-specific effects. For example, two
unrelated families with Arg98ter were found to have a
similar range of MEN1-associated tumors, including
HPT, PET, PIT, and ADR (table 1). The same clini-
cal expression was observed in both families with
Arg527ter. On the other hand, 359del4 (in three fami-
lies) and Arg460ter (in two families) seemed not related
to a homogeneous clinical expression, and we would
expect that such a mutation-specific influence is not a
common phenomenon in MEN1.
MEN1 Patients/Families in Which No Mutation Was
Found
No MEN1 germ-line mutations were found in ∼14%
of MEN1 cases (7/54 MEN1 families and 2/11 MEN1
patients without familial history). When patients and/or
families with atypical MEN1-related disease were con-
sidered, the proportion of negative cases was signifi-
cantly higher, 13/19 (68.5%) (table 3). Large germ-line
MEN1 rearrangements were excluded in all these fam-
ilies/patients, by Southern blot experiments using the
MEN1 cDNA probe and two distinct restriction en-
zymes (EcoRI and KpnI). Multipoint-LOD-score anal-
ysis was performed in two families (F49 and F51) that
have typical features of MEN1 and in which mutations
are missing. Linkage to the MEN1 locus was confirmed
in both families, with LOD scores of 4.99 (for F49) and
2.96 (for F51). Family F52 showed evidence against link-
age to 11q13 (LOD score 2.12), suggesting either ge-
netic heterogeneity (i.e., the identification of a rare
MEN1 family unlinked to 11q13) or the occurrence of
phenocopies. In family F52 the proband is affected by
multifocal pancreatic endocrine tumors, whereas his sis-
ter has a single parathyroid adenoma. The three sons of
the proband share the same MEN1 paternal haplotype
but have no biological/clinical signs of the disease at age
130 years. As shown in table 3, of 12 families with
atypical clinical features and missing MEN1 mutations,
7 (58%) showed intrafamilial associations of HPT and
PIT: one of them (i.e., A14) had a related case affected
by adrenal hyperplasia responsible for Cushing syn-
drome, two (16%) were characterized by isolated oc-
currence of HPT and PET, two (16%) were characterized
by isolated occurrence of either HPT or ADR, and one
(A19) (8%) showed two related cases of isolated PET.
No MEN1 mutation was found in one family with
FIHPT (A8) (table 3). A LOD score of 0.6 in this kindred
did not provide a clear conclusion in favor of linkage
to MEN1. This FIHPT family includes three patients
with primary HPT, two of whom have been treated sur-
gically for multiglandular disease. A long-term follow-
up (x10 years) enables us to exclude any other endo-
crine abnormalities. Four children of age 4–19 years
share the family MEN1 haplotype defined in the three
affected patients but showed no biochemical abnor-
malities in a recent screening.
Discussion
Location and Diversity of MEN1 Germ-Line Mutations
In this study, we have screened 54 MEN1 families, 11
isolated MEN1 patients, and 19 atypical MEN1-related
cases, for germ-line mutations in the MEN1 gene. We
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Table 3
Clinical Description of Families without Identified SCG2 Mutations
Clinical-Features
Category and




F48 HPT, PIT ADR, breast cancer ZES to be confirmed ND
F49 HPT, PET, PIT CNS Probable consanguinity 4.99
F50 HPT, PET/ZES ND
F51 HPT, PET, PIT 2.96
F52 HPT, PET 2.11
F53 HPT, PIT Thyroid cancer Familial mental defect ND
F54 HPT, PIT Familial renal lithiasis ND
I10 HPT, PET, PIT PET-meta Family history unknown ND
I11 HPT, PET, PIT ND
Atypical of MEN1:b
A7 PIT ADR ND
A8 HPT FIHPT .60
A9 HPT, PIT Parathyroid cancer Pituitary macro-adenoma ND
A10 PIT ADR (Conn adenoma) ND
A11 HPT, PIT ND
A12 HPT, PIT Cushing syndrome ND
A13 HPT, PIT Parathyroid single adenoma ND
A14 HPT, PIT ND
A15 HPT, PET ND
A16 HPT, PET ND
A17 PET ZES, glucagonoma, and ectopic secretion of ACTH ND
A18 HPT, PIT ND
A19 HPT, PIT ND
NOTE.—Linkage analysis was performed with 11q13 polymorphic markers—D11S480, D11S1883, PYGM(caga), D11S449,
D11S1889, and D11S913 (from centromere to telomere).
a Posterior probability that family shows linkage to 11q13, as determined by the VITESSE program (version 1.0). NA not applicable.
b Includes isolated lesions.
have identified 52 distinct mutations in a total of 62
MEN1 germ-line alterations observed in this series. As
with regard to the previous study ofBRCA1 andBRCA2
in our laboratory (Serova et al. 1997), HD screening
was used as a first screening method and was shown to
be highly sensitive. The main characteristics of mutations
were comparable to those found in previous reports (Ar-
gawal et al. 1997; Lemmens et al. 1997; Mayr et al.
1997; Shimizu et al. 1997; Bassett et al. 1998) (table 1
and fig. 3). In the present report, most (35/52) germ-line
MEN1 alterations described—including 10/52 nonsense
mutations and 25/52 frameshifts, or deletions, or inser-
tions—are likely to result in a premature translation stop
and in functional loss of the menin protein. The path-
ogenic effect of these mutations could be related to the
presence of at least two nuclear localization signals
(NLS), NLS-1 (codons 479–497) and NLS-2 (codons
588–608), in the C-terminal region of the MEN1-en-
coded protein, which recently has been demonstrated to
be located within the nucleus (Guru et al. 1998). De-
letion constructs of an enhanced green-fluorescent pro-
tein-tagged menin-fusion protein suggest that loss of
NLS and subsequent instability of menin could be one
of the critical events in MEN1 pathogenesis. Of 35 non-
sense and frameshift mutations identified in our study,
27 would result in a truncated menin lacking both NLS-
1 and NLS-2, and 8 NS/FS occur after codon 497 and
delete only the putative NLS-2.
Eight missense point mutations and five in-frame de-
letions were detected in exons 3, 4, and 7–10 and seemed
not to be restricted to specific regions, thus confirming
previous reports (Argawal et al. 1997; Bassett et al.
1998). All missense mutations, together with all in-frame
deletions/insertions except one (1384delAGG), when an-
alyzed with the programs predicting the secondary struc-
ture of the protein (Predict Protein; SOPMA), appeared
to be located either inside or on the border of the pre-
dicted helix structures. This observation suggests that
these seemingly dispersed structures could be of signif-
icance for the MEN1-protein function. However, none
of these amino acid substitutions affect the putative NLS,
suggesting that other functional domains in menin ac-
count for MEN1 pathogenesis.
Four mutations were observed at exon/intron bound-
aries and occurred at splice-junction sites. For one of
them (8931 GrT in intron 4), we were able to dem-
onstrate a complete in-frame deletion of exon 4 (fig. 2).
The mechanism involved in such an exon skipping cor-
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Figure 3 Localization of MEN1 germ-line mutations, from exon 2 to exon 10. Mutation nomenclature is the same as that in table 1.
Exon 1 and the distal part of exon 10 (diagonally hatched boxes) are untranslated regions of the gene, and the coding region is denoted by
nonhatched boxes. The start (ATG) and stop (TGA) sites were localized within exons 2 and 10, respectively. Broken lines represent introns and
the distal part of exon 10 and are not drawn to scale. Mutations are classified as FS, NS, and MS/IF. The splice junction and intronic mutations
are in italics and are denoted as “SpL/Int.” A, Mutations identified in the present study. B, Recurrent mutations identified by our own and
other groups (Argawal et al. 1997; Mayr et al. 1997; Shimizu et al. 1997; Bassett et al. 1998). The sites for recurrent mutations (i.e., hot spots)
in the MEN1 coding sequence are denoted by blackened boxes under the gene structure. Numbers in square brackets after the mutations denote
the number of patients reported for that mutation.
responds to a consequence frequently observed when
one of the splicing sites of an internal exon is affected
(Maquat 1996).
Most mutations occurred once, whereas some of them
were observed in more than one family. When a common
ancestor is excluded by haplotyping analysis, these re-
current mutations might be accounted for by mutational
hot spots in the MEN1 gene. Our data, added to those
from other groups, show 110 recurrent mutations;
7 of them (359del4, Arg98ter, 738del4, Arg260ter,
1650insC, 1650delC, and Arg527ter) have been iden-
tified at least four (and as many as eight) times among
160 mutations described so far (fig. 3). Recurrent frame-
shift insertions or deletions occur in a repetitive motif
(CCCCCCCCG) starting at position 1650 in exon 10.
These mutations might be due to replication errors by
slipped-strand mispairing (Weitzmann et al. 1997). Sim-
ilar mechanism have been suggested for 359del4 and
738del4, in exons 2 and 3, respectively (Bassett et al.
1998). Taken together, our data and those from other
groups indicate the occurrence of multiple and indepen-
dent disease-causing mutations in the MEN1 gene. Un-
like the results with regard to MEN1 families in New-
foundland (Petty et al. 1994; Olufemi et al. 1998), no
founder effect could be found in MEN1, for the majority
of recurrent mutations. Similar observations has been
made elsewhere, in two independent linkage-disequilib-
rium studies—one with 10 Japanese MEN1 families
(Sakurai et al. 1996) and one with 96 European MEN1
families (The European Consortium on MEN1 1997).
Genotype-Phenotype Correlations
No genotype-phenotype correlations were found by
comparison of families having the different types of mu-
tations (table 1 and fig. 3). In our study, the four un-
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related families and one isolated patient with missense
mutations were characterized by the complete MEN1
phenotype, with two or more major lesions (HPT and
PET, with or without PIT). Clinical analysis of five fam-
ilies (F11, F24, F27, F30, and F47) with in-frame de-
letions and of the one family (F16) with complete in-
frame skipping of exon 4 revealed no particular disease
expression. The occurrence of frequently associated le-
sions such as adrenocortical tumors was observed in
families with both early- and late-truncating mutations
(in exons 2, 9, and 10).
Previously we had published an extensive clinical
characterization of the family with the Arg415ter mu-
tation (in exon 9). In this family (F23), patients with
highly malignant thymic carcinoids were observed, and
a medullary ependymoma occurred in a 26-year-old gene
carrier (Giraud et al. 1997). Of five families with mu-
tations leading to truncations in the same region (exon
9), two showed particularly aggressive phenotypes, one
with malignant neuroendocrine tumors and the second
with Cushing syndrome related to malignant ADR, a
compressive pituitary-tumoral process associated with a
meningioma.
These results are in agreement with those from pre-
vious studies (Argawal et al. 1997; Bassett et al. 1998)
and suggest the absence of a clear relationship between
the predicted size of the truncated MEN1 protein and
the clinical expression/severity of the disease. Neverthe-
less, interpretation of genotype-phenotype correlations
could be biased by several factors, including (1) different
clinical follow-up in independent medical centers, (2)
lack of information in some families, (3) age-related pen-
etrance of MEN1, and/or (4) environmental and socio-
economic factors that could affect the clinical expression
of the disease among gene carriers.
Clinical States in the Absence of MEN1 Mutation
We failed to find MEN1 mutations in seven familial
MEN 1 patients and two isolated MEN1 patients. In
cases of families F49 and F51, linked to 11q13 (with
LOD scores 4.99 and 2.96, respectively), it is likely that
a mutation in the MEN1 gene has been missed. It there-
fore is possible that mutations responsible for the disease
in these families occur outside the MEN1 sequence
screened in this study. Another possibility is a large germ-
line deletion, either within or including the MEN1 gene,
that escapes detection by PCR-based sequencing. In
Southern-blot analysis of MEN1 patients without an
identified MEN1 mutation, we failed to detect any ab-
normalities, which suggests that such a deletion could
be rare and/or infrequently detected by gene-dosage
techniques such as quantitative PCR, as recently has
been shown elsewhere (Kishi et al. 1998). Family F52
showed a negative LOD score with 11q13 markers. This
finding might reflect either genetic heterogeneity of the
MEN1 syndrome or the presence of phenocopies in this
family. Phenocopies have to be considered carefully in
MEN1, mainly because of the high frequency of com-
mon lesions such as pHPT and prolactinoma in the non-
MEN1 population (Teh et al. 1996b; Stock et al. 1997).
Frequently encountered MEN1 manifestations in fami-
lies and patients withoutMEN1mutations were primary
HPT and pituitary lesions (table 3). Elsewhere, heredi-
tary hyperparathyroidism and prolactinoma has been
described as a genetic variant of MEN1, so called
MEN1Burin (Petty et al. 1994), but other recent studies
have suggested that some families with unusual features
of the syndrome and frequent expression of pituitary
tumors do not shown linkage to 11q13 (Stock et al.
1997). Genetic heterogeneity in inherited endocrine tu-
mors could be another explanation for MEN1 manifes-
tations in families without MEN1 germ-line mutations.
No MEN1 germ-line mutation was found in a case of
FIHPT (table 3). Similar observations in five unrelated
FIHPT families have been published elsewhere (Argawal
et al. 1997). The absence of MEN1 mutations could be
assessed on the basis of the fact that, in our FIHPT case,
MEN1 was excluded by a careful long-term (x10 years)
follow-up of all three probands. It cannot be ruled out
that some cases of FIHPT are allelic variants of MEN1.
On the other hand, FIHPT has been described elsewhere
as a feature of at least two independent genetic syn-
dromes, named “HPRT-1” (familial hyperparathyroid-
ism) and “HPRT-2” (HPT–jaw-tumor syndromes),
which are characterized by recurrent parathyroid ade-
noma and an increased risk of parathyroid carcinoma
(Wassif et al. 1993; Teh et al. 1996a). The FIHPT family
that we studied did not show any of the associated le-
sions, such as jaw tumors and/or renal cancers, that else-
where had been described in HPRT-2. Further studies
will be necessary to establish the incidence of various
forms of FIHPT.
Conclusions
Germ-line mutation analysis of theMEN1 gene is now
possible in families predisposed to MEN1 and, in the
majority of MEN1 families and isolated cases, will be a
useful tool for both earlier detection of MEN1-related
tumors and appropriate genetic counseling. Further clin-
ical issues concern the frequency of germ-line MEN1
mutations among patients with a single endocrine lesion,
a situation that appears to be the most common in clin-
ical practice (Sheperd 1991). MEN1 inactivation also
has been suggested as a primary pathogenic event in a
significant proportion of sporadic endocrine tumors.
This has been demonstrated in 20%–30% of sporadic
parathyroid tumors (Heppner et al. 1997), 17%–33%
of insulinomas/gastrinomas (Zhuang et al. 1997b; Hess-
mann et al. 1998), and 36% of lung carcinoids (Debe-
lenko et al. 1997). On the other hand, inactivation of
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MEN1 does not appear to play a prominent role in spo-
radic pituitary tumors (Zhuang et al. 1997a; Prezant et
al. 1998). The type and location of MEN1 mutations
identified in sporadic tumors were similar to those of
germ-line mutations and thus are supposed to have sim-
ilar functional consequences at the somatic level. Our
findings, added to those from other groups, point out
the diversity of MEN1 mutations identified to date. Fur-
ther progress on the MEN1 gene promotor(s) and reg-
ulatory sequences, as well as functional studies of the
MEN1 gene together with selected mutations, will be
critical steps for a better understanding of its role in
endocrine tumoral pathogenesis.
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